Background. Dihydroartemisinin-piperaquine (DP) is a new and relatively inexpensive artemisinin-containing fixed-combination antimalarial treatment. An adult treatment course contained 6.4 mg/kg dihydroartemisinin (DHA), which is 140% lower than the level in most artemisinin-containing combinations. This raised the possibility that the efficacy of the current coformulation may not be optimal in the treatment of multidrug-resistant falciparum malaria.
in Southeast Asia. Piperaquine, an orally active bisquinoline discovered by Rhône-Poulenc in the early 1960s, was developed for clinical use in 1973. It is structurally related to chloroquine, with a similar mechanism of action-that is, through the chemical inhibition of parasite heme detoxification. However, piperaquine is active against highly chloroquine-resistant Plasmodium falciparum [1] [2] [3] . The estimated terminal elimination half-life in adults is 17 days [4] . Piperaquine phosphate (PQP) replaced chloroquine as the recommended treatment for falciparum malaria in China in 1978 and was used extensively for mass prophylaxis and treatment. Reported adverse events are generally similar to those observed with chloroquine, although pruritus is uncommon [3] . The results of 2 recent randomized clinical trials that assessed DP in Cambodia and Vietnam [5, 6] indicate excellent tolerability and high rates of cure of multidrug-resistant falciparum malaria. This combination is now part of the nationally recommended antimalarialtreatment policy in Vietnam.
Artemisinin derivatives have an excellent safety profile in humans, which has been documented in a large number of randomized, controlled trials and in more-extensive community use [7] . Dihydroartemisinin (DHA) is the active metabolite of the more widely used artesunate and artemether and is manufactured as an oral antimalarial drug in China. When taken orally, artesunate is almost entirely hydrolysed to DHA and, so, has equivalent therapeutic efficacy [8] . In the present study, the dose of DHA in an adult treatment course of DP was ∼6.4 mg/kg given over the course of 48 h, which is ∼40% lower than that in current artesunate-containing combination antimalarial regimens (10-12 mg/kg). This dose was chosen empirically and, so, raises the possibility that the DHA content may be insufficient for optimum antimalarial activity, especially in areas where P. falciparum is highly drug resistant.
To determine whether the dose of DHA in the combination was adequate to produce maximum efficacy for treatment of uncomplicated but multidrug-resistant falciparum malaria, we have conducted a detailed dose-optimization study of DP in the Bangkok Hospital for Tropical Diseases and a large community-based evaluation of patients of all ages on the northwestern border of Thailand. The hospital-based study allowed a more detailed safety evaluation, and the community study featured a broad representation of ages and a larger number of patients with a 63-day follow-up. Secondary objectives were to assess the safety and tolerability of the DP combination.
PATIENTS, MATERIALS, AND METHODS

Center 1: Hospital for Tropical Diseases, Faculty of Tropical Medicine, Mahidol University, Bangkok (inpatient study).
Patients presenting with symptoms of malaria were included if they had asexual forms of P. falciparum detected in their blood smear, were 114 years old, and weighed 140 kg.
Center 2: Shoklo Malaria Research Unit, Mae Sot, Thailand (outpatient study). Patients 1-65 years old with symptomatic infections were recruited from 4 clinics along the Thai-Myanmar border, an area of unstable low and seasonal malaria transmission [9] . Two clinics were in Mae La, a camp for 38,000 displaced persons mainly of the Karen ethnic group, and 2 clinics were in Thai villages, Mawker Thai and Muruchai (which are ∼100 km south of the camp), mainly serving migrant workers from Myanmar.
Exclusion criteria for both studies included pregnancy or lactation, у4% of red blood cells (RBCs) being parasitized, signs or symptoms of severe malaria, treatment with mefloquine during the previous 60 days, or contraindications to treatment with mefloquine. In center 1, patients were excluded if sulfonamides or 4-aminoquinolines were present in urine on admission, indicating pretreatment. Informed, written consent was obtained from all subjects or from a parent/guardian in the case of children. Both studies were approved by the Faculty of Tropical Medicine Ethical Committee, Mahidol University, and the study at center 2 was also approved by the Oxford Tropical Research Ethics Committee.
Procedures
The duration of symptoms before presentation, any drugs taken, baseline symptoms, and physical examination were recorded on a standard case-record form.
Center 1. All patients were admitted to the hospital. Oral temperature was monitored every 6 h. Parasite counts were performed every 12 h until found to be negative, then daily for 28 days. A malaria parasite count per microliter, for a thick blood smear, was obtained by calculation against the white blood cell (WBC) count.
Center 2. Tympanic temperature was recorded (Braun Thermoscan LF40) once daily. Samples of capillary blood were obtained for blood smears, hematocrit was determined, and 3 blood spots were obtained on 3-mm Whatman filter paper, for polymerase chain reaction (PCR) genotyping. Thick and thin blood smears stained with Giemsa were read, and counts were expressed as the number of parasites per 1000 RBCs or, for lower parasitemias, per 500 WBCs. Adults had 5 mL of EDTA blood obtained for parasite culture.
Antimalarial Drug Treatment
Mefloquine plus artesunate (MAS3) group. The MAS3 group received mefloquine (Mequin; Atlantic Laboratories; mefloquine hydrochloride; 250-mg tablets) at 8 mg/kg once daily plus artesunate (Guilin Factory no. 1; 50-mg tablets) at 4 mg/ kg once daily, for 3 days. DP group. The DP group received DP (Artekin; Holleykin Pharmaceutical). One tablet contained 40 mg of DHA and 320 mg of PQP. Subjects at center 1 received 4 doses of 2 tablets at 0, 8, 24, and 48 h (approximate total adult dose, 6 mg/kg DHA and 48 mg/kg PQP). Subjects at center 2 received a weight-based regimen of 1.6 mg/kg DHA and 12.8 mg/kg PQP, rounded up or down to the nearest half tablet (i.e., total dose, 6.4 mg/kg DHA and 51.2 mg/kg PQP).
DP+ group At center 1, DP was used in the same dose as in the DP group, with 100 mg of artesunate added to each dose. At center 2, DP was again used at the same dose, but with DHA (Cotecxin; Beijing COTEC New Technology Corporation; 20-mg tablets) used according to weight, to increase the total daily dose of DHA to 4 mg/kg. Thus, assuming complete artesunate biotransformation, at center 2, the total DHA 
Randomization
Patients were randomly allocated in blocks of 6 (center 1) or 9 (center 2) to receive 1 of the 3 treatments. The randomization was computer generated (STATA; version 7; StataCorp), and the treatment allocation was concealed in sealed envelopes labeled with the study code. In center 2, a subgroup of patients in the DP group were randomized to have hematological and biochemical monitoring. This allocation was also concealed.
The investigators recruiting patients were therefore blinded to the treatment and investigation allocations. Laboratory staff members reading the blood smears had no knowledge of the treatment received.
Monitoring for Adverse Events
Adverse events were defined as signs and symptoms that occurred or became more severe after treatment started. All patients in center 1 and a subset of 55 patients in the DP group at center 2 had complete blood counts, urea, electrolyte, and creatinine determinations, and liver-function tests performed at baseline and day 7. Thirty-two patients from the DP group at center 2 had electrocardiographic (ECG) monitoring before the first dose of DP, 4 h later, and 4 h after the final dose. Selection was nonrandom, as ECG monitoring was only available at 1 site. ECG intervals were measured automatically by the machine, and QT and RR intervals were cross-checked manually for 10% of the recordings selected at random and for all recordings with a QTc reading, by the machine, of 1450 ms in males or 1470 ms in females. The QTc interval was calculated by use of Bazett's formula:
Center 1. Patients were followed in the hospital for 28 days. Time to clearance of fever was taken as the period from the start of treatment until the oral temperature remained !37.5ЊC for 48 h. Center 2. Temperature and blood smears were checked daily (at ∼24-h intervals) until clearance of fever and parasitemia. Thereafter, patients attended the clinic weekly for 9 weeks.
Management of Reappearance of P. falciparum during Follow-Up
Center 1. Since all patients were kept in a hospital outside the transmission area, reappearance of parasites was assumed to be recrudescence of the original infection and was treated with oral quinine (10 mg salt/kg 3 times daily) plus tetracycline (4 mg/kg 3 times daily) for 1 week.
Center 2. Patients who experienced clinical treatment failure were treated with artesunate (2 mg/kg once daily) plus doxycycline (4 mg/kg once daily) for 7 days or artesunate alone if !8 years old. PCR genotyping for allelic variation in 3 loci (merozoite surface proteins 1 and 2 and glutamate-rich protein) was used to distinguish recrudescence from reinfection, as described elsewhere [10] .
Laboratory Quality Assessment
In center 2, baseline and treatment-failure blood smears were cross-checked by staff members who were unaware of the initial report. 
Study End points and Statistical Analysis
The main outcome measures were the day-28 cure rates in center 1 and the day-63 PCR-adjusted cure rates in center 2, by use of an intention-to-treat analysis. The study at center 1 was an inpatient study, with patients recruited from a wide geographical area, and so extended follow-up was not feasible. Clinical and parasitological responses and the incidence of anemia and adverse events were compared.
Normally distributed continuous variables were compared using analysis of variance (ANOVA), and nonnormally distributed continuous variables were compared using Mann-Whitney U or Kruskal-Wallis test, as appropriate. Differences in proportions were compared using the x 2 test. PCR-adjusted cure rates were calculated using Kaplan-Meier survival analysis with log rank test for significance. Statistical programs used were SPSS for Windows (version 11.0; SPSS), Epi Info (version 1.0; Centers for Disease Control and Prevention), and STATA (version 7; StataCorp). In center 1, 23 patients (11.4%) were unable to complete the 28-day follow-up because of reasons related to family or employment. In center 2, 68 patients (12.8%) were unable to complete 9 weeks of follow-up, with 26 (4.9%) not completing 28 days. The main reason for loss to follow-up was change of address. Four patients were unable to complete the treatment and did not return for follow-up. Patients arriving up to 3 days late for the final appointment (day 66) were included in the day-63 analysis.
RESULTS
Between
One patient was withdrawn from the study at baseline and excluded from the analysis because his parasitemia was higher than the upper limit for inclusion and had been misreported from the initial blood smear. A patient in the DP group who had mixed P. falciparum and P. malariae infection was found to have a baseline parasitemia below the limit for inclusion when cross-checked. Two patients were treated for incidental bacterial infections with doxycycline during follow-up and, on that day, were excluded from further analysis of cure rate be- cause of the possibility of suppressing a recrudescent infection. When the slides were cross-checked, 2 patients withdrawn for reappearance of P. falciparum during follow-up were found to have had a P. vivax infection. Confirmatory PCR genotyping failed to detect any P. falciparum DNA. One patient died from gunshot wounds, at day 28 of follow-up.
Baseline Characteristics
The baseline characteristics of the study populations are summarized in table 1. Characteristics were similar in all treatment groups, with a preponderance of males. In the study at center 2, there were 182 children !15 years old and 26 children !5 years old. The mean DHA and PQP doses received per treatment course in center 1 were 6.2 and 49.8 mg/kg, respectively, in the DP group and 13.7 (assumes artesunate is equivalent to DHA) and 48.9 mg/kg, respectively, in the DP+ group. The median (range) DHA and PQP doses in center 2 were 6.4 (4.44-9.23) and 51.2 (35.6-73.9) mg/kg, respectively, in the DP group and 12 (8.9-13.9) and 51.2 (35.6-73.9) mg/kg, respectively, in the DP+ group. In center 2, the median number of clinic visits per patient was 12 in all groups.
Clinical and Parasitological Responses (Table 2)
Center 1. The mean (SD) times to clearance of fever in the MAS3, DP, and DP+ groups were 25.2 (28.4), 24.8 (24.7), and 24.4 (15.1) h respectively. Clearance of parasitemia did not differ significantly between the groups, with a mean (SD) time of 36.9 (13.7) h in the MAS3 group, 35 (16.2) h in the DP group, and 37.1 (15.1) h in the DP+ group. Center 2. There was no difference in times to clearance of fever on the basis of once-daily measurements, with 99% of patients afebrile by day 2. A higher proportion of patients had blood smears negative for malaria on day 1 in the groups receiving DP or DP+ than in the group receiving MAS3 (P p ). In the MAS3 group, a 9-year-old boy with 0.5% parasi-.006 temia at baseline did not achieve a 75% reduction in parasitemia by day 2 or clear his parasitemia by day 7 and was therefore considered to have experienced early treatment failure. (table 4) . The median (range) age of the 9 patients who experienced treatment failure in the MAS3 group was 6 (2-36) years, compared with 25 (5-60) years in the DP group. In other respects, the baseline characteristics of the patients who experienced treatment failure did not differ significantly from those of other patients.
Efficacy (
The median (range) times to reinfection were 56 (4-63) days in the MAS3 group, 56 (28-63) days in the DP group, and 49 (21-63) days in the DP+ group (figure 2). The patient in the MAS3 group who did not clear his parasitemia by day 7 did not respond to artesunate plus doxycycline; he was then treated successfully with atovaquone-proguanil. In vitro drug-susceptibility testing of blood samples obtained at baseline showed IC 50 values of 12.1 ng/mL for mefloquine and 0.21 ng/mL for artesunate, which are well within the range indicating drug sensitivity.
Anemia (Figure 3)
There was a decrease in mean hematocrit from baseline to day 7, followed by recovery in all groups. During the first week, the median (25th-75th percentile) decrease in hematocrit in the MAS3 group was 9.4% (2.6%-14.3%), that in the DP group was 6.3% (0%-13.6%), and that in the DP+ group was 9.6% (2.9%-15.9%) ( ). P p .21
Gametocyte Carriage
At center 2, at baseline, 13 patients (7.4%) in the MAS3 group, 11 (6.1%) in the DP group, and 5 (2.9%) in the DP+ group had gametocytes detected in their blood smears. Subsequent gametocytemia was suppressed effectively. Only 2 patients in the MAS3 group and 3 in the DP group developed patent gametocytemia during follow-up.
Mixed Infections
At center 2, 47 patients (8.9%) had a mixed infection at baseline: 42 with P. falciparum and P. vivax and 5 with P. falciparum and P. malariae. Patients with mixed P. falciparum and P. vivax infection at baseline were younger than those with P. falciparum infection alone (median [range] age, 13.5 vs. 20 years) ( ). Other baseline characteristics, including du-P p .012 ration of fever before presentation, were similar in both groups. Seventeen patients (36%) with a mixed infection had a second P. vivax infection or relapse during follow-up: 6 in the MAS3 
Adverse Events
There were no serious drug-related adverse events. Center 1. No patient experienced early vomiting. Minor symptoms of nausea, headache, and dizziness occurred in !10% of patients in all groups and disappeared by day 4.
Center 2. In all groups, !3% of patients experienced early vomiting. Between the start of treatment and day 28, dizziness, nausea, vomiting, and sleep disturbance were reported more commonly in the MAS3 group; however, the difference between groups only reached statistical significance for sleep disturbance ( ) (table 5) . Abdominal pain was reported by 12.3% P p .008 of patients in the DP group, 4.5% in the MAS3 group, and 7.5% in the DP+ group ( ) ( figure 4 ). There were 2 P p .025 cases of urticaria reported: the first, 4 h after the first dose of MAS3, and the second, 30 min after the third dose of DP. There was 1 accidental pregnancy exposure in the DP+ group, at ∼11 weeks of gestation, determined by ultrasound dating. A urinary pregnancy test performed at baseline was reported as negative. This 36-year-old woman had a threatened abortion 9 weeks later but went on to deliver a 2.5-kg healthy male infant. kg). Changes in complete blood count between days 0 and 7 were compatible with the recovery phase of acute malaria, with a mean (SD) decrease in hematocrit of 5% (11.6%) and increases of the WBC and platelet counts to normal values. There were minor fluctuations in liver-function tests after treatment in some patients in the DP group. Of note, levels of alanine aminotransferase showed a median increase of 21% (range, Ϫ90% to +412%) from baseline to day 7. In 4 patients, day-7 levels were у50% higher than the upper limit of normal. The largest increase was observed in a 2-year-old girl whose alanine aminotransferase level increased to 124 U/L from 35 U/L (normal range, 5-40 U/ L), on day 7, but decreased again to 35 U/L on day 14. There was no corresponding increase in other liver enzyme levels or bilirubin concentration. There was no biochemical evidence of nephrotoxicity in any of the patients.
Electrocardiography
A total of 32 patients (26 males and 6 females) in the DP group had serial ECGs performed, at 0 h, 4 h after the first dose, and 4 h after the final dose. Their median (range) age was 24 (6-60) years. Manual cross-checking of 10% of the ECGs selected randomly and all ECGs for which the machine recorded a prolonged QTc found a trend for the machine to overestimate the QT interval, reading a median value of 1 ms longer (range, Ϫ5 to 12 ms) than the QT interval calculated manually. The median (range) heart rate at baseline was 89 (61-120) beats/ minute, and the median (range) QTc was 417 (368-456) ms. The mean and median QTc values 4 h after the first dose were fractionally lower than those at baseline, and there was a median increase of 2 ms of the QTc, compared with that at baseline and at 52 h (i.e., 4 h after the final dose of treatment). Five patients had a prolonged QTc recorded at any time point. A manual check found only 1 to be slightly prolonged: a 23-yearold male with a QTc interval of 460 ms on his last recording, compared with 420 ms at baseline. There were no other ECG changes of note.
DISCUSSION
In the present study, DP was a well-tolerated, safe, and highly effective treatment for uncomplicated multidrug-resistant falciparum malaria in adults and children. P. falciparum in Southeast Asia is highly multidrug resistant. The addition of extra artemisinin derivative (either as artesunate or DHA) to the recommended dose did not improve efficacy significantly. This is very reassuring, since experience to date with artemisinincontaining combinations has been with higher doses of artesunate or DHA, and there was concern that the dose in DP might not be optimal. The patients in the treatment arm that included additional artemisinin received ∼12 mg/kg DHA (or equivalent), which was double the DHA dose of the DP arm and comparable to the dose in established artemisinin-containing combination treatments. This increased dose of DHA may explain the more-rapid clearance of parasitemia among patients in the DP+ group at center 2. However, there was no difference in clearance of parasitemia between the groups at center 1, on the basis of the results of the blood smears performed every 12 h, and patients receiving 12 mg/kg MAS3 had slightly slower clearance of parasitemia than did patients in both DP groups. Thus, although it remains possible that the current dose of DHA does not give the maximum effect in all patients, this does not adversely affect cure rates, which were very high in all 3 groups. This also emphasizes the continuing excellent efficacy of MAS3 over a 10-year period of deployment. DP is clearly a very promising new treatment, despite the high levels of quinoline resistance in Southeast Asia. Cure rates may be even higher than 196%, as 3 of the 5 indeterminate PCR results occurred in the DP group, which lowered the cure rate estimate by ∼1%. The majority of treatment failures occurred late, between days 29 and 63, which emphasizes the usefulness of extended follow-up in assessing antimalarial drug efficacy with these slowly eliminated antimalarial drugs. It was not possible to identify any predictors of treatment failure, as the numbers of failures were very small and drug levels were not measured in this cohort.
Piperaquine is structurally related to chloroquine. In vitro animal experiments have not found significant cross-resistance to piperaquine when this was used to treat chloroquine-resistant P. berghei in rodent models [2] . This has been supported here by the finding of high efficacy in an area where parasites are highly resistant to chloroquine. Studies in animals and healthy human patients have shown the bioavailability of oral DHA to be lower than that of oral artesunate, although, in patients, they are approximately equal [8, 11, 12] . Formulation and excipients in the tabletting are critical. In animal models, DHA and piperaquine show additive efficacy. [3] .
The effects of DP in suppressing relapses of P. vivax in patients with mixed infections were similar to those observed with chloroquine, with reappearances of P. vivax at ∼6 weeks. This suggests suppression of the first relapse, which usually occurs at 3 weeks in Southeast Asia [13] . Very few patients had detectable gametocytemia during the study, which reflects the potent gametocytocidal properties of the artemisinin derivatives.
DP was well tolerated, with a low incidence of mild adverse events, which were mainly upper gastrointestinal and were similar to those reported in other studies. Patients in the DP group reported significantly more nonsevere abdominal pain than did those in the MAS3 group. This is considered to be the main individual dose-limiting adverse event of PQP, on the basis of the early, extensive Chinese experience with this drug as monotherapy. Interestingly, the prevalence was lower in the DP+ group. The finding of hepatotoxicity in preclinical animal studies was not reproduced at therapeutic dosage in humans in these studies, although there was biochemical evidence of mild increases in transaminases in a small number of patients. In one young patient, there was an asymptomatic 3-fold increase in alanine aminotransferase levels from baseline to day 7. Whether this was drug or disease related cannot be ascertained. It will be important to continue to screen actively for hepatotoxicity in further prospective studies of the drug. There was no electrocardiographic evidence of cardiotoxicity or concerns over QT prolongation.
It has been established that the ratio of DHA to PQP in the combination is satisfactory, but more pharmacokinetic data on both compounds are needed to optimize the dosing regimen and to characterize the sources of individual pharmacokinetic variance and determine their pharmacodynamic correlates. In particular, more data on use in children are needed. It would also be appealing, from an operational perspective, if the dosing regimen could be simplified to give the drug once daily for 3 days. DP is considerably less expensive than other artemisinin combinations, which are reliably effective. It therefore has the potential to become the drug of choice for falciparum malaria in African countries where chloroquine and sulfadoxinepyrimethamine (SP) are rapidly becoming useless. The mean weights of adult patients included in these studies are likely to be lower than those in many African countries, so the optimal tablet dosing will need further study. That DP is a fixed coformulation with a 3-day (у48 h) dosing regimen means that it is a straightforward treatment to adhere to. Minor adverse events are few, and no severe adverse events have been reported in studies to date. In terms of cost, DP is currently less than half the cost of artemether-lumefantrine or MAS3 and compares favorably to artesunate-SP or artesunate-amodiaquine (AQ) in price. As DP is more effective against drug-resistant infections, it would be expected to have a much longer useful therapeutic life than artesunate-SP or artesunate-AQ. Piperaquine has been widely used only in China before, and, so, the absence of this drug as a monotherapy in most malaria-endemic countries puts it at a great advantage if it is deployed. Another advantage, compared with SP combinations, is that it does not prolong gametocyte carriage, with implications for transmission of malaria. A low-cost, well-tolerated, and highly effective treatment fulfils the criteria required to reverse the current trend of increasing malaria morbidity and mortality.
